FOLR2 and acute myeloid leukemia: Briefly, these researchers reported the isolation of a high-affinity scFv (2.48 nM) specific for FRβ and demonstrated that CAR-Ts equipped with this scFv showed pronounced tumoricidal capacity against FRβ-positive AML cells in comparison with FRβ-redirected CAR-Ts that harbored a low-affinity scFv as their targeting domain, in preclinical experiments (91).